Albireo reports q4 and year-end 2021 financial results and business update

Boston, march 01, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended december 31, 2021.
ALBO Ratings Summary
ALBO Quant Ranking